Imfinzi hits on disease-free survival, but BCG won't be displaced.
ApexOnco Front Page
Recent articles
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
One step forward, two steps back for biotech.
